Health

Researchers at the Van Andel Institute have discovered a significant finding about glucose, a sugar commonly found in the body, and its potent role in enhancing the ability of T cells, a type of immune cell, to combat cancer. On September 2, 2025, the work was released in the esteemed journal Cell Metabolism.

The World Health Organization (WHO) has officially recommended the use of Ienacapavir, a long-acting injectable drug, for HIV prevention. This milestone announcement was made on July 14 during the 13th International AIDS Society Conference in Kigali. The recommendation aims to help countries adopt lenacapavir, especially in high-burden areas and among vulnerable populations. Lenacapavir, marketed as Sunlenca for treatment and Yeztugo for prevention, is a capsid inhibitor approved in 2022 for certain HIV treatments. Its unique mechanism blocks HIV replication by targeting the virus's protective protein shell. Unlike daily oral pills, lenacapavir is administered only twice a year via injection and has shown near-complete protection in clinical trials.

A recent study has revealed that metabolic health indicators, particularly even slight elevations in blood sugar, play a central role in altering the reproductive and sexual functions of aging men. The findings were unveiled during the 2025 annual meeting of the Endocrine Society (ENDO), held from July 12 to 15 at the Moscone Convention Center in San Francisco, California, USA.